 Operational highlights
• 
Lead cancer drug candidate SRA737 (formerly CCT245737), 
a novel Chk1 inhibitor, licensed for clinical development and 
commercialisation to NASDAQ-listed company Sierra Oncology, 
Inc. by Sareum’s co-investment partner, CRT Pioneer Fund 
(September 2016).
• 
Sareum is eligible to receive 27.5% of up to US$328.5 million 
in upfront, development and commercialisation milestone 
payments as well as royalties on sales.
• 
An upfront payment of US$7 million and a first milestone payment 
of US$2 million have already been received from Sierra Oncology 
(September 2016 and January 2017 respectively). 
• 
Good progress reported by Sierra Oncology in the two ongoing 
clinical studies with SRA737 as both a monotherapy and in combination 
with chemotherapy in a range of cancers (June 2017). 
• 
Patents protecting SRA737 were granted in the USA and Europe 
(May 2017), extending the protection period to 2033 in the USA.
• 
Successful outcome from feasibility study with TYK2 inhibitors in 
T -Cell Acute Lymphoblastic Leukaemia (T -ALL). In disease models, 
Sareum’s compounds demonstrated good oral bioavailability, 
were well tolerated and showed tumour reduction of up to 80% 
(October 2016). These results support the further advancement 
of the programme.
• 
Further patent grants for Aurora+FL T3 kinase programme in Japan, 
Singapore, China, and Hong Kong, completing intellectual property 
protection for the candidate in all major territories.
Financial highlights
• 
Maiden profit (after taxation) on ordinary activities of £400k 
(2016: loss of £1.05 million). 
• 
Net assets at period end were £2.34 million (2016: £1.86 million), 
of which £2.31 million comprised cash at bank (2016: £1.25 million).
• 
£1.50 million received from Sierra Oncology as the Company’s 
share of the US$7 million upfront payment from the out-licensing 
agreement for SRA737 (September 2016). Milestone payment 
of £450k received (share of US$2 million payment) following 
the successful transfer of the two ongoing Phase 1 clinical trials 
of SRA737. 
• 
Received £229k in unspent funds previously invested in clinical 
development of Chk1 upon the out-licensing of SRA737.
Strategic report
1 Highlights
2 At a Glance
4  Chairman’s Statement
5 Spotlight on SRA737
6 CEO’s Research Update
8 Business Model
9 Our Strategy
9 Key Performance Indicators
10 Principal Risks
Governance
11 Directors and Company Information
12 Group Strategic Report
13 Report of the Directors
14 Corporate Governance Report
15 Remuneration Committee Report
Financial statements
17 Report of the Independent Auditor
19  Consolidated Statement 
of Comprehensive Income
20 Consolidated Balance Sheet
21 Company Balance Sheet
22  Consolidated Statement 
of Changes in Equity
22  Company Statement 
of Changes in Equity
23 Consolidated Cash Flow Statement
23 Company Cash Flow Statement
24  Notes to the Consolidated 
Financial Statements
visit us online:
www.sareum.com
Our website provides comprehensive 
information about our business, 
including the latest news on our 
drug development programmes 
and investor information.
Highlights
STRATEGIC REPORT
Sareum Holdings plc  
Annual Report and Accounts 2017 1
